243 related articles for article (PubMed ID: 24421886)
1. A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers.
Thorstensson R; Trollfors B; Al-Tawil N; Jahnmatz M; Bergström J; Ljungman M; Törner A; Wehlin L; Van Broekhoven A; Bosman F; Debrie AS; Mielcarek N; Locht C
PLoS One; 2014; 9(1):e83449. PubMed ID: 24421886
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study.
Jahnmatz M; Richert L; Al-Tawil N; Storsaeter J; Colin C; Bauduin C; Thalen M; Solovay K; Rubin K; Mielcarek N; Thorstensson R; Locht C;
Lancet Infect Dis; 2020 Nov; 20(11):1290-1301. PubMed ID: 32687804
[TBL] [Abstract][Full Text] [Related]
3. B-cell responses after intranasal vaccination with the novel attenuated Bordetella pertussis vaccine strain BPZE1 in a randomized phase I clinical trial.
Jahnmatz M; Amu S; Ljungman M; Wehlin L; Chiodi F; Mielcarek N; Locht C; Thorstensson R
Vaccine; 2014 Jun; 32(27):3350-6. PubMed ID: 24793938
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus-diphtheria-acellular pertussis vaccine: a randomised, double-blind, phase 2b trial.
Keech C; Miller VE; Rizzardi B; Hoyle C; Pryor MJ; Ferrand J; Solovay K; Thalen M; Noviello S; Goldstein P; Gorringe A; Cavell B; He Q; Barkoff AM; Rubin K; Locht C
Lancet; 2023 Mar; 401(10379):843-855. PubMed ID: 36906345
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of live, attenuated intranasal Bordetella pertussis vaccine (BPZE1) in healthy adults.
Buddy Creech C; Jimenez-Truque N; Kown N; Sokolow K; Brady EJ; Yoder S; Solovay K; Rubin K; Noviello S; Hensel E; Selamawi S; Bakare A; Makowski M; Lu K
Vaccine; 2022 Nov; 40(47):6740-6746. PubMed ID: 36220716
[TBL] [Abstract][Full Text] [Related]
6. Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3.
Debrie AS; Coutte L; Raze D; Mooi F; Alexander F; Gorringe A; Mielcarek N; Locht C
Vaccine; 2018 Mar; 36(11):1345-1352. PubMed ID: 29433898
[TBL] [Abstract][Full Text] [Related]
7. Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1.
Feunou PF; Kammoun H; Debrie AS; Mielcarek N; Locht C
Vaccine; 2010 Oct; 28(43):7047-53. PubMed ID: 20708998
[TBL] [Abstract][Full Text] [Related]
8. Heterologous prime-boost immunization with live attenuated B. pertussis BPZE1 followed by acellular pertussis vaccine in mice.
Feunou PF; Kammoun H; Debrie AS; Locht C
Vaccine; 2014 Jul; 32(34):4281-8. PubMed ID: 24950361
[TBL] [Abstract][Full Text] [Related]
9. Protective role of adenylate cyclase in the context of a live pertussis vaccine candidate.
Lim A; Ng JK; Locht C; Alonso S
Microbes Infect; 2014 Jan; 16(1):51-60. PubMed ID: 24140230
[TBL] [Abstract][Full Text] [Related]
10. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough.
Mielcarek N; Debrie AS; Raze D; Bertout J; Rouanet C; Younes AB; Creusy C; Engle J; Goldman WE; Locht C
PLoS Pathog; 2006 Jul; 2(7):e65. PubMed ID: 16839199
[TBL] [Abstract][Full Text] [Related]
11. Attenuated Bordetella pertussis vaccine protects against respiratory syncytial virus disease via an IL-17-dependent mechanism.
Schnoeller C; Roux X; Sawant D; Raze D; Olszewska W; Locht C; Openshaw PJ
Am J Respir Crit Care Med; 2014 Jan; 189(2):194-202. PubMed ID: 24261996
[TBL] [Abstract][Full Text] [Related]
12. Attenuated Bordetella pertussis BPZE1 as a live vehicle for heterologous vaccine antigens delivery through the nasal route.
Li R; Lim A; Alonso S
Bioeng Bugs; 2011; 2(6):315-9. PubMed ID: 22067832
[TBL] [Abstract][Full Text] [Related]
13. Early Protection against Pertussis Induced by Live Attenuated
Debrie AS; Mielcarek N; Lecher S; Roux X; Sirard JC; Locht C
J Immunol; 2019 Dec; 203(12):3293-3300. PubMed ID: 31732529
[TBL] [Abstract][Full Text] [Related]
14. Live Attenuated Pertussis Vaccine BPZE1 Protects Baboons Against Bordetella pertussis Disease and Infection.
Locht C; Papin JF; Lecher S; Debrie AS; Thalen M; Solovay K; Rubin K; Mielcarek N
J Infect Dis; 2017 Jul; 216(1):117-124. PubMed ID: 28535276
[TBL] [Abstract][Full Text] [Related]
15. Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice.
Mielcarek N; Debrie AS; Mahieux S; Locht C
Clin Vaccine Immunol; 2010 Mar; 17(3):317-24. PubMed ID: 20107007
[TBL] [Abstract][Full Text] [Related]
16. A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice.
Skerry CM; Cassidy JP; English K; Feunou-Feunou P; Locht C; Mahon BP
Clin Vaccine Immunol; 2009 Sep; 16(9):1344-51. PubMed ID: 19625486
[TBL] [Abstract][Full Text] [Related]
17. Attenuated Bordetella pertussis vaccine strain BPZE1 modulates allergen-induced immunity and prevents allergic pulmonary pathology in a murine model.
Kavanagh H; Noone C; Cahill E; English K; Locht C; Mahon BP
Clin Exp Allergy; 2010 Jun; 40(6):933-41. PubMed ID: 20184606
[TBL] [Abstract][Full Text] [Related]
18. A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model.
Skerry CM; Mahon BP
Clin Vaccine Immunol; 2011 Feb; 18(2):187-93. PubMed ID: 21147936
[TBL] [Abstract][Full Text] [Related]
19. IL-17-dependent SIgA-mediated protection against nasal Bordetella pertussis infection by live attenuated BPZE1 vaccine.
Solans L; Debrie AS; Borkner L; Aguiló N; Thiriard A; Coutte L; Uranga S; Trottein F; Martín C; Mills KHG; Locht C
Mucosal Immunol; 2018 Nov; 11(6):1753-1762. PubMed ID: 30115992
[TBL] [Abstract][Full Text] [Related]
20. Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans.
Lin A; Apostolovic D; Jahnmatz M; Liang F; Ols S; Tecleab T; Wu C; van Hage M; Solovay K; Rubin K; Locht C; Thorstensson R; Thalen M; Loré K
J Clin Invest; 2020 May; 130(5):2332-2346. PubMed ID: 31945015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
